BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld
Home
» Sangamo Drops SB-509 After Phase IIb Fails; Other ZFPs OK
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Sangamo Drops SB-509 After Phase IIb Fails; Other ZFPs OK
Oct. 4, 2011
By
Trista Morrison
No Comments
Despite a Phase IIb failure in diabetic neuropathy that prompted Sangamo BioSciences Inc. to drop lead drug SB-509, analysts believe earlier-stage programs may give the firm's zinc finger protein (ZFP) platform a better chance to shine.
BioWorld